

## Wednesday, April 22

08:30-10:00

### **CF 101 Clinical Focus Session Early-stage HCC**

- 101.1 Pathology of early HCC
- 101.2 Imaging of early HCC
- 101.3 Why and how to biopsy
- 101.4 What to do when on the waiting list for transplantation
- 101.5 Evidence from literature: resection vs. ablation for early HCC

10:30-12:00

### **CF 201 Clinical Focus Session Intermediate HCC**

- 201.1 Critical appraisal of EASL vs. Hong Kong classification
- 201.2 Where does ablation fit in intermediate stage HCC?
- 201.3 Drug-eluting beads vs. conventional TACE
- 201.4 Where does radioembolisation fit in intermediate stage HCC?
- 201.5 Current evidence of systemic therapy in intermediate stage HCC

10:30-12:00

### **TF 202 Technical Focus Session Top tips**

- 202.1 Radioembolisation: preparation
- 202.2 Radioembolisation: treatment
- 202.3 DEB TACE
- 202.4 Lung ablation
- 202.5 Kidney ablation
- 202.6 Spinal ablation
- 202.7 Bone consolidation

10:30-12:00

### **TA-How 1 Hands-on Workshop Image-guided tumour ablation - MSK**

13:00-14:30

**Satellite Symposia**

15:00-16:30

**IS 401 Interactive Session**  
**Multidisciplinary Tumour Board: HCC**

15:00-16:30

**TF 402 Technical Focus Session**  
**Ablation: current status and future horizons**

- 402.1 Radiofrequency ablation
- 402.2 Electroporation
- 402.3 Microwaves
- 402.4 HIFU
- 402.5 Cryoablation
- 402.6 Immunomodulation with ablation

15:00-16:30

**TA-HoW 2 Hands-on Workshop**  
**Image-guided tumour ablation - lung**

17:00-18:30

**CF 501 Clinical Focus Session**  
**How to follow up patients: clinical and imaging**

- 501.1 Radioembolisation for CRC
- 501.2 TACE for HCC
- 501.3 Ablation of colorectal liver metastases
- 501.4 Bone ablation
- 501.5 Ablation of lung metastases

17:00-18:30

**CF 502 Clinical Focus Session**  
**Symptomatic cancer treatment**

- 502.1 Systemic pain medication: a practical guide
- 502.2 Evidence-base of radiation therapy for pain
- 502.3 Nerve blocks
- 502.4 Percutaneous management of pleural effusion
- 502.5 Percutaneous management of malignant ascites

18:30-19:00

**Satellite Symposia**

**Thursday, April 23** TOP

07:45-08:15

**Satellite Symposia**

08:30-10:00

**CF 801 Clinical Focus Session**  
**Lung metastases**

- 801.1 How to evaluate lung function before and after surgery, SBRT and ablation?
- 801.2 Surgery in lung metastases
- 801.3 Is ablation of lung metastases a first line therapy?
- 801.4 Imaging follow-up after treatments: surgery, SBRT, ablation
- 801.5 Evidence from comparative trials for lung metastases

08:30-10:00

**VL 802 Video Learning**  
**How I do it: liver**

- 802.1 Liver ablation + venous occlusion
- 802.2 Combined cTACE and ablation
- 802.3 DEB-TACE
- 802.4 Y-90
- 802.5 PVE

10:30-11:30

**HL 901 Honorary Lecture**

10:30-12:00

**TA-HoW  
3 Hands-on Workshop**

**Image-guided tumour ablation - liver**

11:30-12:00

**The best IO papers of 2014**

13:00-14:30

**Satellite Symposia**

15:00-16:30

**IS 1101 Interactive Session**

**Multidisciplinary Tumour Board: lung**

15:00-16:30

**JS 1102 Joint Session**

**Essence of interventional oncology**

Joint session with JSIR (Japanese Society of  
Interventional Radiology)

- 1102.1 Concept of TACE based on micro-vasculature of HCC
- 1102.2 Intra-arterial infusion therapy - background and challenges
- 1102.3 Interventional palliative treatment
- 1102.4 Ablation - combination with other IR techniques
- 1102.5 Clinical trials for evidences of IO

15:00-16:30

**TA-HoW  
4 Hands-on Workshop**

**Image-guided tumour ablation - kidney**

17:00-18:30

**CF 1201 Clinical Focus Session**

## **Ablation: evidence for expanding the boundaries**

- 1201.1 Thyroid
- 1201.2 Breast
- 1201.3 Adrenal
- 1201.4 Lymphnodes
- 1201.5 Prostate

17:00-18:30

### **CF 1202 Clinical Focus Session Fundamentals of oncology**

Conventional chemotherapy

- 1202.1 Targeted therapy: what an interventional oncologist should know
- 1202.2
- 1202.3 Phase I, II, III trials: do you really know the differences?
- 1202.4 How to define response in interventional oncology trials
- 1202.5 How endpoints in interventional oncology may differ from medical oncology trials

18:30-19:00

### **Satellite Symposia**

## **Friday, April 24** TOP

07:45-08:15

### **Satellite Symposia**

08:30-10:00

### **CF 1501 Clinical Focus Session MSK tumours**

- 1501.1 Evidence for ablation in local control
- 1501.2 Evidence for radiation therapy in local control
- 1501.3 When does HIFU fit in?
- 1501.4 Bone consolidation: cementoplasty vs. osteosynthesis
- 1501.5 When to use embolisation in combination with ablation

08:30-10:00

**JS 1502 Joint Session**

ECIO invites ESMO (European Society for Medical Oncology)

Programme to be announced.

10:30-12:00

**CF 1601 Clinical Focus Session  
Kidney cancer**

- 1601.1 Renal mass: surveillance protocols, indications for biopsy and thresholds for treatment
- 1601.2 Evidence-based nephron-sparing surgery
- 1601.3 Evidence-based ablation vs. resection outcomes
- 1601.4 Systemic and adjuvant treatment in RCC
- 1601.5 Follow-up after ablation: imaging and clinical

10:30-12:00

**CF 1602 Clinical Focus Session  
Intra-arterial therapies: what is the evidence?**

- 1602.1 Liver metastases from melanoma: what is the role of intra-arterial therapies today?
- 1602.2 Neuroendocrine liver metastases: which intra-arterial therapy for which patient?
- 1602.3 Intra-arterial therapy in lung tumours: where do we stand?
- 1602.4 Cholangiolar carcinoma: the relative role of TACE vs systemic therapy
- 1602.5 Intra-arterial therapy in liver metastases: the 5 best papers of the past year

13:00-14:30

**Satellite Symposia**

15:00-16:30

**VL 1801 Video Learning**  
**How I do it: lung and kidney**

- 1801.1 Lung RFA/MWA
- 1801.2 Lung cryoablation
- 1801.3 Kidney RFA/MWA
- 1801.4 Kidney cryoablation
- 1801.5 Percutaneous pancreas IRE

15:00-16:30

**CF 1802 Clinical Focus Session**  
**Quality pays: clinical excellence saves money**

Improve quality without added cost: patient pathway in IO

- 1802.1 Improve quality without added cost: a structured IO
- 1802.2 report
- 1802.3 Cost effectiveness in patient care: what is it, and how to measure it in
- 1802.4 interventional oncology?
- 1802.5 Disinvestment in medicine, and the need for evidence  
The science underpinning interventional oncology: how should we prove the value of what we do?

17:00-18:30

**IS 1901 Interactive Session**  
**Management of complications I**

- 1901.1 Liver TACE
- 1901.2 Liver ablation
- 1901.3 Radioembolisation
- 1901.4 GI complications

17:00-18:30

**JS 1902 Joint Session**  
**Molecular oncology and translation into the clinic**  
Joint session with WCIO (World Conference on  
Interventional Oncology)

- 1902.1 Oncogenic pathways and their relevance to interventional oncology
- 1902.2 Tumour hypoxia
- 1902.3 Immunomodulation and radioembolisation
- 1902.4 Tumour metabolism
- 1902.5 Image-guided drug activation
- 1902.6 DNA repair inhibitor

18:30-19:00

**Satellite Symposia**

**Saturday, April 25** TOP

08:30-10:00

**IS 2101 Interactive Session**  
**Management of complications II**

- 2101.1 MSK tumour management
- 2101.2 Liver ablation
- 2101.3 Kidney ablation
- 2101.4 Lung ablation

10:30-12:00

**VL 2201 Video Learning**  
**How I do it: pain management**

- 2201.1 Splanchnic neurolysis
- 2201.2 Vertebroplasty and ablation
- 2201.3 PleurX
- 2201.4 Pelvic osteosynthesis
- 2201.5 Hypogastric neurolysis